M&A rebound: How Ireland is bucking the global trend with rate cuts set to fuel more deals

In early February this year, news emerged that Chanelle Pharma, Ireland’s largest indigenous manufacturer of generic drugs for animal and human health, had been sold to Exponent, the British private equity fund, as part of a mega €300 million deal.

For Michael Burke, the founder and chief executive of Chanelle, the sale of his family-owned company was the culmination of a 40-year career in business. Despite its scale, the sale of the generics manufacturer had ...